Jesus Corral Jaime, MD, reviews real-world survival and response data for cemiplimab monotherapy from the CEMI-LUNG study.
|Slideshows|January 15, 2018
Oncology Pulse Survey Results
Author(s)Cancer Network Editors
Last month we asked our readers: If you were to start your career again, would you still choose oncology, would you pick a different specialty, or would you perhaps not choose a career in medicine at all? Here are the results.
Advertisement
Advertisement
Related to this article
At the Big Ten CRC Summit, VK Gadi, MD, PhD, explained why functional drug testing and genomic profiling should be used together in oncology.
First-line pembrolizumab monotherapy did not significantly improve overall survival vs carboplatin plus paclitaxel at the first analysis in dMMR advanced or recurrent endometrial cancer.
Findings from the phase 1 KANDLELIT-001 study support further investigation of calderasib plus pembrolizumab in KRAS G12C-mutated metastatic NSCLC.
Sacituzumab tirumotecan improved survival vs chemotherapy in patients with advanced or recurrent endometrial cancer after platinum and immunotherapy.
Oral vitamin C improved OS in patients with CCUS or lower-risk myeloid malignancies in the EVITA trial despite missing the clonal growth primary end point.
In KEYNOTE-412, early ctDNA clearance was linked with better survival with pembrolizumab plus chemoradiotherapy in HPV-negative head and neck cancer.
Phase 3 TALAPRO-3 data support the FDA approval of talazoparib/enzalutamide in HRR gene-altered metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Talazoparib/Enzalutamide for HRR Gene-Altered Metastatic Prostate Cancer
2
Ivonescimab Combo Improves Survival in Advanced Biliary Tract Cancer
3
Exploring The Use of GLP-1 Receptor Agonists in Breast Cancer Care
4
Sac-TMT Improves Survival vs Chemotherapy in Pretreated Endometrial Cancer
5